Stifel analyst Benjamin J. Burnett reiterated a Hold rating on bluebird bio (NASDAQ: BLUE) after the company announced the planned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE